The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Approach to MRD assessment in multiple myeloma when NGS is not available
Mattia D’Agostino, MD, University of Turin, Turin, Italy, gives guidance on assessing measurable residual disease (MRD) in multiple myeloma when next-generation sequencing (NGS) is not available. Dr D’Agostino suggests that clinicians should use next-generation flow instead and discusses best practices to ensure accurate interpretation of results. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are many countries in which NGS cannot be done by physicians regarding MRD in the bone marrow. In many of these countries, NGF is the only way that a physician could look into MRD. So my suggestion is that NGF can be done, but you have to do next generation flow according to the Euroflow protocol. And another thing is that you have to reach 2.10 to the minus 6 and to acquire at least 10 million cells in order to be sure that your NGF results reflect what the NGS reflects regarding MRD negativity...
There are many countries in which NGS cannot be done by physicians regarding MRD in the bone marrow. In many of these countries, NGF is the only way that a physician could look into MRD. So my suggestion is that NGF can be done, but you have to do next generation flow according to the Euroflow protocol. And another thing is that you have to reach 2.10 to the minus 6 and to acquire at least 10 million cells in order to be sure that your NGF results reflect what the NGS reflects regarding MRD negativity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
M.D. has received honoraria from GlaxoSmithKline, Sanofi, and Janssen; and has served on the advisory boards for GlaxoSmithKline, Sanofi, and Bristol Myers Squibb.
